The tail-suspension test: A model for characterizing antidepressant activity in mice

Neuromethods

Volumn 42, Issue , 2009, Pages 119-137

  O'Leary, Olivia F ^a   Cryan, John F ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Antidepressant; Automation; Gender; High throughput; Immobility; Strain; Tail suspension test

Indexed keywords

IMIPRAMINE;

ANIMAL BEHAVIOR; BEHAVIOR CHANGE; C57BL 6 MOUSE; DEPRESSION; EXPERIMENTAL TEST; FORCED SWIMMING TEST; HIGH THROUGHPUT SCREENING; IMMOBILIZATION; LEARNED HELPLESSNESS; LOCOMOTION; MOTOR COORDINATION; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; REVIEW; ROTAROD TEST; SCREENING TEST; TAIL SUSPENSION TEST;

ANIMALIA; MUS;

EID: 70349838040     PISSN: 08932336     EISSN: 19406045     Source Type: Book Series    
DOI: 10.1007/978-1-60761-303-9_7     Document Type: Review

References (86)

1. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 1985;85(3):367-370
2. Steru L, Chermat R, Thierry B, et al. The automated Tail Suspension Test: a computerized device which differentiates psychotropic drugs. Progress in Neuro-Psychopharmacology & Biological Psychiatry 1987;11(6):659-671
3. Porsolt RD, Chermat R, Lenegre A, Avril I, Janvier S, Steru L. Use of the automated tail suspension test for the primary screening of psychotropic agents. Archives Internationales de Pharmacodynamie et de Therapie 1987;288(1):11-30. (Pubitemid 17134783)
4. Chermat R, Thierry B, Mico JA, Steru L, Simon P. Adaptation of the tail suspension test to the rat. Journal de Pharmacologie 1986;17(3):348-350 (Pubitemid 17175387)
5. Varty GB, Cohen-Williams ME, Hunter JC. The antidepressant-like effects of neurokinin NK1 receptor antagonists in a gerbil tail suspension test. Behavioural Pharmacology 2003;14(1):87-95.
6. Cryan JF, Mombereau C, Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neuroscience and Biobehavioral Reviews 2005;29(4-5):571-625.
7. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Archives Internationales de Pharmacodynamie et de Therapie 1977;229(2):327-336
8. Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977;266(5604):730-732
9. O'Leary OF, Bechtholt AJ, Crowley JJ, Hill TE, Page ME, Lucki I. Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugs in the mouse tail suspension test. Psychopharmacology (Berl) 2007;192(3):357-371
10. O'Leary OF, Bechtholt AJ, Crowley JJ, Valentino RJ, Lucki I. The role of noradrenergic tone in the dorsal raphe nucleus of the mouse in the acute behavioral effects of antidepressant drugs. European Neuropsychopharmacology 2007;17(3):215-226
11. Cryan JF, O'Leary OF, Jin SH, et al. Norepinephrine- deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. Proceedings of the National Academy of Sciences of the United States of America 2004;101(21):8186-8191
12. Perrault G, Morel E, Zivkovic B, Sanger DJ. Activity of litoxetine and other serotonin uptake inhibitors in the tail suspension test in mice. Pharmacology, biochemistry, and behavior 1992;42(1):45-47
13. Teste JF, Martin I, Rinjard P. Electrotherapy in mice: dopaminergic and noradrenergic effects in the Tail Suspension Test. Fundamental & clinical pharmacology 1990;4(1):39-47.
14. El Yacoubi M, Bouali S, Popa D, et al. Behavioral, neurochemical, and electrophysiological characterization of a genetic mouse model of depression. Proceedings of the National Academy of Sciences of the United States of America 2003;100(10):6227-6232
15. Liu X, Stancliffe D, Lee S, Mathur S, Gershenfeld HK. Genetic dissection of the tail suspension test: a mouse model of stress vulnerability and antidepressant response. Biological psychiatry 2007;62(1):81-91.
16. Cryan JF, Mombereau C. In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. Molecular Psychiatry 2004;9(4):326-357
17. Porsolt RD, AntonG, BlavetN, Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. European Journal of Pharmacology 1978;47(4):379-391
18. Thierry B, Steru L, Chermat R, Simon P. Searching-waiting strategy: a candidate for an evolutionary model of depression? Behavioral andNeural Biology 1984;41(2):180-189
19. Lucki I. A prescription to resist proscriptions for murine models of depression. Psychopharmacology (Berl) 2001;153(3):395-398
20. Dixon AK. Ethological strategies for defence in animals and humans: their role in some psychiatric disorders. The British Journal ofMedical Psychology 1998;71 (Pt 4):417-445
21. Gilbert P, Allan S. The role of defeat and entrapment (arrested flight) in depression: an exploration of an evolutionary view. Psychological Medicine 1998;28(3):585-598
22. Weingartner H, Silberman E. Models of cognitive impairment: cognitive changes in depression. Psychopharmacology Bulletin 1982;18(2):27-42.
23. Vaugeois JM, Odievre C, Loisel L, Costentin J. A genetic mouse model of helplessness sensitive to imipramine. European Journal of Pharmacology 1996; 316(2-3):R1-2.
24. Yoshikawa T, Watanabe A, Ishitsuka Y, Nakaya A, Nakatani N. Identification of multiple genetic loci linked to the propensity for "behavioral despair" in mice. Genome research 2002;12(3):357-366
25. McKinney WT, Jr., Bunney WE, Jr. Animal model of depression. I. Review of evidence: implications for research. Archives of General Psychiatry 1969;21(2):240-248
26. Willner P, Mitchell PJ. The validity of animal models of predisposition to depression. Behavioural Pharmacology 2002;13(3):169-188
27. Geyer M, Markou A. The role of preclinical models in the development of psychotropic drugs. In: Bloom F, Kupfer D, eds. Psychopharmacology: The Fifth Generation of Progress New York; Raven Press. 2000; 445-455
28. McKinney WT. Overview of the past contributions of animal models and their changing place in psychiatry. Seminars in Clinical Neuropsychiatry 2001;6(1):68-78.
29. Willner P. Animal models of depression: an overview. Pharmacology & Therapeutics 1990;45(3):425-455
30. Geyer M, Markou A. Animal models of psychiatric disorders. In: Bloom F, Kupfer D, eds. Psychopharmacology: The Fourth Generation of Progress Raven Press. 1995;787-798
31. Sarter M, Bruno J. Animal models in biological psychiatry. In: D'haenen H, Boer Jd, Westenberg H, P PW, eds. Textbook of Biological Psychiatry: John Wiley & Sons. 2002:37-44.
32. Vaugeois JM, Passera G, Zuccaro F, Costentin J. Individual differences in response to imipramine in the mouse tail suspension test. Psychopharmacology (Berl) 1997;134(4):387-391
33. Swiergiel AH, Leskov IL, Dunn AJ. Effects of chronic and acute stressors and CRF on depression-like behavior in mice. Behavioural Brain Research 2008;186(1):32-40.
34. Kamei J, Miyata S, Morita K, Saitoh A, Takeda H. Effects of selective serotonin reuptake inhibitors on immobility time in the tail suspension test in streptozotocin-induced diabetic mice. Pharmacology, Biochemistry, and Behavior 2003;75(2):247-254
35. Miyata S, Hirano S, Kamei J. Diabetes attenuates the antidepressant-like effect mediated by the activation of 5-HT1A receptor in the mouse tail suspension test. Neuropsychopharmacology 2004;29(3):461-469 (Pubitemid 38365923)
36. Yamano M, Yuki H, Yasuda S, Miyata K. Corticotropin-releasing hormone receptors mediate consensus interferonalpha YM643-induced depression-like behavior in mice. The Journal of Pharmacology and Experimental Therapeutics 2000;292(1):181-187
37. Dunn AJ, Swiergiel AH. Effects of interleukin- 1 and endotoxin in the forced swim and tail suspension tests in mice. Pharmacology, Biochemistry, and Behavior 2005;81(3):688-693
38. Cryan JF, Hoyer D, Markou A. Withdrawal from chronic amphetamine induces depressive- like behavioral effects in rodents. Biological Psychiatry 2003;54(1):49-58.
39. Naudon L, El Yacoubi M, Vaugeois JM, Leroux-Nicollet I, Costentin J. A chronic treatment with fluoxetine decreases 5- HT(1A) receptors labeling in mice selected as a genetic model of helplessness. Brain Research 2002;936(1-2):68-75.
40. Cryan JF, Leonard BE. 5-HT1A and beyond: the role of serotonin and its receptors in depression and the antidepressant response. Human Psychopharmacology 2000;15(2):113-135
41. Thomson F, Craighead M. Innovative approaches for the treatment of depression: targeting the HPA axis. Neurochemical Research 2008;33(4):691-707.
42. Crowley JJ, Blendy JA, Lucki I. Strain-dependent antidepressant-like effects of citalopram in themouse tail suspension test. Psychopharmacology (Berl) 2005;183(2):257-264
43. Crowley JJ, Brodkin ES, Blendy JA, Berrettini WH, Lucki I. Pharmacogenomic evaluation of the antidepressant citalopram in the mouse tail suspension test. Neuropsychopharmacology 2006;31(11):2433-2442
44. Liu X, Gershenfeld HK. Genetic differences in the tail-suspension test and its relationship to imipramine response among 11 inbred strains of mice. Biological Psychiatry 2001;49(7):575-581
45. Yamada K, Watanabe A, Iwayama-Shigeno Y, Yoshikawa T. Evidence of association between gamma-aminobutyric acid type A receptor genes located on 5q34 and female patients with mood disorders. Neuroscience Letters 2003;349(1):9-12.
46. Edenberg HJ, Foroud T, Conneally PM, et al. Initial genomic scan of the NIMH genetics initiative bipolar pedigrees: chromosomes 3, 5, 15, 16, 17, and 22. American Journal of Medical Genetics 1997;74(3):238-246 (Pubitemid 27251221)
47. Lad HV, Liu L, Paya-Cano JL, Fernandes C, Schalkwyk LC. Quantitative traits for the tail suspension test: automation, optimization, and BXD RI mapping. Mammalian Genome 2007;18(6-7):482-491
48. van der Heyden JA, Molewijk E, Olivier B. Strain differences in response to drugs in the tail suspension test for antidepressant activity. Psychopharmacology (Berl) 1987;92(1):127-130
49. Crowley JJ, Jones MD, O'Leary OF, Lucki I. Automated tests for measuring the effects of antidepressants in mice. Pharmacology, Biochemistry, and Behavior 2004;78(2):269-274
50. Chaki S, Nakazato A, Kennis L, et al. Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/ CRA0450. European Journal of Pharmacology 2004;485(1-3):145-158
51. Nielsen DM, Carey GJ, Gold LH. Antidepressant- like activity of corticotropin-releasing factor type-1 receptor antagonists in mice. European Journal of Pharmacology 2004;499(1-2):135-146
52. Zobel AW, Nickel T, Kunzel HE, et al. Effects of the high-affinity corticotropinreleasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. Journal of Psychiatric Research 2000;34(3):171-181
53. Nielsen DM. Corticotropin-releasing factor type-1 receptor antagonists: the next class of antidepressants? Life Sciences 2006;78(9):909-919
54. Czeh B, Fuchs E, Simon M. NK1 receptor antagonists under investigation for the treatment of affective disorders. Expert Opinion on Investigational Drugs 2006;15(5):479-486
55. Binneman B, Feltner D, Kolluri S, Shi Y, Qiu R, Stiger T. A 6-week randomized, placebo- controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. The American Journal of Psychiatry 2008;165(5):617-620
56. Katz MM, Koslow SH, Maas JW, et al. The timing, specificity and clinical prediction of tricyclic drug effects in depression. Psychological Medicine 1987;17(2):297-309.
57. Harmer CJ, Bhagwagar Z, Perrett DI, Vollm BA, Cowen PJ, Goodwin GM. Acute SSRI administration affects the processing of social cues in healthy volunteers. Neuropsychopharmacology 2003;28(1): 148-152
58. Harmer CJ, Hill SA, Taylor MJ, Cowen PJ, Goodwin GM. Toward a neuropsychological theory of antidepressant drug action: increase in positive emotional bias after potentiation of norepinephrine activity. The American Journal of Psychiatry 2003;160(5):990-992
59. Crabbe JC, Wahlsten D, Dudek BC. Genetics of mouse behavior: interactions with laboratory environment. Science (New York) 1999;284(5420):1670-1672
60. Wahlsten D, Metten P, Phillips TJ, et al. Different data from different labs: lessons from studies of gene-environment interaction. Journal of Neurobiology 2003;54(1): 283-311.
61. Ripoll N, David DJ, Dailly E, Hascoet M, Bourin M. Antidepressant-like effects in various mice strains in the tail suspension test. Behavioural Brain Research 2003;143(2):193-200. (Pubitemid 36937164)
62. Teste JF, Pelsy-Johann I, Decelle T, Boulu RG. Anti-immobility activity of different antidepressant drugs using the tail suspension test in normal or reserpinized mice. Fundamental & Clinical Pharmacology 1993;7(5):219-226
63. Cryan JF, Valentino RJ, Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neuroscience and Biobehavioral Reviews 2005; 29(4-5):547-569
64. Cryan JF, Markou A, Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends in Pharmacological Sciences 2002;23(5): 238-245
65. Overmier JB, Seligman ME. Effects of inescapable shock upon subsequent escape and avoidance responding. Journal of Comparative and Physiological Psychology 1967; 63(1):28-33.
66. Vollmayr B, Henn FA. Learned helplessness in the rat: improvements in validity and reliability. Brain Research Brain Research Protocols 2001;8(1):1-7.
67. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology (Berl) 1997;134(4):319-329
68. Kelly JP, Wrynn AS, Leonard BE. The olfactory bulbectomized rat as a model of depression: an update. Pharmacology & Therapeutics 1997;74(3):299-316.
69. Weissman MM, Olfson M. Depression in women: implications for health care research. Science (NewYork) 1995;269(5225):799-801.
70. Pelloux Y, Hagues G, Costentin J, Duterte- Boucher D. Helplessness in the tail suspension test is associated with an increase in ethanol intake and its rewarding effect in female mice. Alcoholism, Clinical and Experimental Research 2005;29(3):378-388
71. David DJ, Nic Dhonnchadha BA, Jolliet P, Hascoet M, Bourin M. Are there gender differences in the temperature profile of mice after acute antidepressant administration and exposure to two animal models of depression? Behavioural Brain Research 2001;119(2):203-211
72. Caldarone BJ, Karthigeyan K, Harrist A, et al. Sex differences in response to oral amitriptyline in three animal models of depression in C57BL/6 J mice. Psychopharmacology (Berl) 2003;170(1):94-101.
73. Jones MD, Lucki I. Sex differences in the regulation of serotonergic transmission and behavior in 5-HT receptor knockout mice. Neuropsychopharmacology 2005; 30(6):1039-1047
74. Nichols DE, Nichols CD. Serotonin receptors. Chemical Reviews 2008;108(5):1614-1641
75. Meziane H, Ouagazzal AM, Aubert L, Wietrzych M, Krezel W. Estrous cycle effects on behavior of C57BL/6 J and BALB/cByJ female mice: implications for phenotyping strategies. Genes, Brain, and Behavior 2007;6(2):192-200.
76. Bernardi M, Vergoni AV, Sandrini M, Tagliavini S, Bertolini A. Influence of ovariectomy, estradiol and progesterone on the behavior of mice in an experimental model of depression. Physiology & Behavior 1989;45(5):1067-1068
77. Crawley JN, Belknap JK, Collins A, et al. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology (Berl) 1997;132(2):107-124
78. Mayorga AJ, Lucki I. Limitations on the use of the C57BL/6 mouse in the tail suspension test. Psychopharmacology (Berl) 2001; 155(1):110-112
79. Juszczak GR, Sliwa AT, Wolak P, Tymosiak- Zielinska A, Lisowski P, Swiergiel AH. The usage of video analysis system for detection of immobility in the tail suspension test in mice. Pharmacology, Biochemistry, and Behavior 2006;85(2):332-338
80. Bai F, Li X, Clay M, LindstromT, Skolnick P. Intra- and interstrain differences in models of "behavioral despair". Pharmacology, Biochemistry, and Behavior 2001;70(2-3):187-192
81. Trullas R, Jackson B, Skolnick P. Genetic differences in a tail suspension test for evaluating antidepressant activity. Psychopharmacology (Berl) 1989;99(2):287-288
82. Liu X, Gershenfeld HK. An exploratory factor analysis of the Tail Suspension Test in 12 inbred strains of mice and an F2 intercross. Brain Research Bulletin 2003;60(3):223-231
83. Sallee FR, Pollock BG. Clinical pharmacokinetics of imipramine and desipramine. Clinical Pharmacokinetics 1990;18(5):346-364
84. Popoli M, Brunello N, Perez J, Racagni G. Second messenger-regulated protein kinases in the brain: their functional role and the action of antidepressant drugs. Journal of Neurochemistry 2000;74(1):21-33.
85. Mombereau C, Kaupmann K, Froestl W, Sansig G, van der Putten H, Cryan JF. Genetic and pharmacological evidence of a role for GABA(B) receptors in the modulation of anxiety- and antidepressant- like behavior. Neuropsychopharmacology 2004;29(6):1050-1062
86. Porsolt R, Lenegre A. Behavioral models of depression. In: Elliott J, Heal D, Marsden C, eds. Experimental approaches to anxiety and depression. London: Wiley; 1992:73-85